Literature DB >> 30368730

CRP and LOX-1: a Mechanism for Increasing the Tumorigenic Potential of Colorectal Cancer Carcinoma Cell Line.

Mousa Ghazi-Khanloosani1, Ahmad Reza Bandegi1,2, Parviz Kokhaei3,4, Mehdi Barati3, Abbas Pakdel5,6.   

Abstract

Chronic inflammation and dyslipidemia are associated with an increase in the incidence of colorectal cancer (CRC). Serum C- reactive protein (CRP) and oxidized low-density lipoprotein (oxLDL), as Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) ligands, increase during inflammation and dyslipidemia, respectively. To evaluate the effects of CRP on the expression of important genes involved in the development of CRC, the CRC cell line, LS174T, was treated with the commercial CRP. Based on the Real-time PCR data, in the presence of CRP, LOX-1, CEA, MMP1, and MMP2 mRNA expression significantly increased, compared to the control group. Moreover, in the presence of CRP, secretion, and expression of CEA in the cell lysate and conditioned media increased in a concentration-dependent manner. The results of flow cytometry showed that expression of LOX-1 receptors at the cell surface increased significantly in the presence of 10 mg/L of CRP. However, inhibition of LOX-1 receptors with a specific monoclonal antibody reduced the effects of CRP on protein/mRNA expression. In conclusion, Increased CRP level, can potentially elevate the expression of important genes in CRC by stimulating LOX-1 receptors.

Entities:  

Keywords:  C-reactive protein; Carcinoembryonic antigen; LOX-1 receptor; Matrix metalloproteinase; Oxidized low density lipoprotein; Tumorigenic potential

Mesh:

Substances:

Year:  2018        PMID: 30368730     DOI: 10.1007/s12253-018-0507-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  41 in total

1.  A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases.

Authors:  Heather A Hirsch; Dimitrios Iliopoulos; Amita Joshi; Yong Zhang; Savina A Jaeger; Martha Bulyk; Philip N Tsichlis; X Shirley Liu; Kevin Struhl
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

2.  Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2.

Authors:  X H Zhu; J M Wang; S S Yang; F F Wang; J L Hu; S N Xin; H Men; G F Lu; X L Lan; D Zhang; X Y Wang; W T Liao; Y Q Ding; L Liang
Journal:  Int J Cancer       Date:  2017-04-21       Impact factor: 7.396

3.  Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.

Authors:  In-Ho Kim; Ji Eun Lee; Ji Hyun Yang; Joon Won Jeong; Sangmi Ro; Myung Ah Lee
Journal:  Asia Pac J Clin Oncol       Date:  2017-10-18       Impact factor: 2.601

4.  Regulation of carcinoembryonic antigen release from colorectal cancer cells.

Authors:  Abbas Pakdel; Fakhraddin Naghibalhossaini; Pooneh Mokarram; Mansooreh Jaberipour; Ahmad Hosseini
Journal:  Mol Biol Rep       Date:  2011-07-02       Impact factor: 2.316

5.  Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects.

Authors:  Yoshiko Fujita; Akemi Kakino; Norihisa Nishimichi; Saburo Yamaguchi; Yuko Sato; Sachiko Machida; Luciano Cominacini; Yves Delneste; Haruo Matsuda; Tatsuya Sawamura
Journal:  Clin Chem       Date:  2008-12-12       Impact factor: 8.327

6.  Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies.

Authors:  Yong-Zhong Guo; Lei Pan; Chang-Jun Du; Dun-Qiang Ren; Xiao-Mei Xie
Journal:  Asian Pac J Cancer Prev       Date:  2013

7.  Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells.

Authors:  Cary B Aarons; Olga Bajenova; Charles Andrews; Stanley Heydrick; Kristen N Bushell; Karen L Reed; Peter Thomas; James M Becker; Arthur F Stucchi
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

8.  Elevated pre-treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer.

Authors:  Maosong Lin; Junxing Huang; Jiayi Zhu; Hongzhang Shen
Journal:  Exp Ther Med       Date:  2013-10-16       Impact factor: 2.447

Review 9.  LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.

Authors:  Barbara Rizzacasa; Elena Morini; Sabina Pucci; Michela Murdocca; Giuseppe Novelli; Francesca Amati
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

10.  Lectin-like oxidized low-density lipoprotein receptor-1 facilitates metastasis of gastric cancer through driving epithelial-mesenchymal transition and PI3K/Akt/GSK3β activation.

Authors:  Can Li; Jie Zhang; Hao Wu; Lili Li; Caiting Yang; Shushu Song; Peike Peng; Miaomiao Shao; Mingming Zhang; Junjie Zhao; Ran Zhao; Weicheng Wu; Yuanyuan Ruan; Lan Wang; Jianxin Gu
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

View more
  3 in total

1.  Pro-inflammatory cytokine polymorphisms in ONECUT2 and HNF4A and primary colorectal carcinoma: a post genome-wide gene-lifestyle interaction study.

Authors:  Su Yon Jung; Jeanette C Papp; Eric M Sobel; Matteo Pellegrini; Herbert Yu; Zuo-Feng Zhang
Journal:  Am J Cancer Res       Date:  2020-09-01       Impact factor: 6.166

2.  Genetically determined elevated C-reactive protein associated with primary colorectal cancer risk: Mendelian randomization with lifestyle interactions.

Authors:  Su Yon Jung; Herbert Yu; Matteo Pellegrini; Jeanette C Papp; Eric M Sobel; Zuo-Feng Zhang
Journal:  Am J Cancer Res       Date:  2021-04-15       Impact factor: 6.166

3.  The prognostic role of C-reactive protein in patients with head and neck squamous cell carcinoma: A meta-analysis.

Authors:  Yanglan Chen; Rong Cong; Chengjian Ji; Wenhua Ruan
Journal:  Cancer Med       Date:  2020-11-17       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.